Antibody-drug conjugate news and latest updates

News and Trends 9 Dec 2022

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression. Siddhartha Mukherjee, assistant professor of Medicine at Columbia University Medical Center in the Department of Medicine and Division […]

December 9, 2022 - 4 minutesmins - By Jim Cornall

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […]

December 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 7 Dec 2022

BiVictriX identifies development lead for ADC cancer program

BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has identified a development lead for its BVX001 program. The lead was developed using BiVictriX’s proprietary Bi-Cygni approach, which aims to generate the next-generation of antibody drug conjugates (ADCs) with superior […]

December 7, 2022 - 2 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 30 Nov 2022

SOTIO exercises option on ADC program

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies of solid tumor indications. In November 2021, SOTIO and LCB entered into a multi-target exclusive collaboration and license […]

November 30, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Nov 2022

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […]

November 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 14 Oct 2022

Mablink Bioscience receives €31M series A funding for ADC pipeline

French biotech company Mablink Bioscience has raised €31 million ($30.3 million) in series A funding to advance its lead candidate to the clinic and to build a pipeline of antibody drug conjugates (ADCs). The round was led by Sofinnova Partners and Mérieux Equity Partners. Existing shareholders Elaia Partners, UI-Investissement/Pertinence Invest 2 (advised by Mérieux Equity […]

October 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Oct 2022

Trial starts for treatment of warm autoimmune hemolytic anemia

China-based Hutchmed has started a phase 2/3 trial of sovleplenib in adults with a disorder called warm antibody autoimmune hemolytic anemia (wAIHA). The autoimmune disorder can lead to anemia and currently has limited treatment options. It causes premature destruction of healthy red blood cells and the rate of production of new cells in the bone […]

October 10, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Oct 2022

Araris Biotech closes $24M financing round for ADCs

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date. The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Sep 2022

Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors

Pheon Therapeutics launched today (September 28) following the closing of a $68 million series A funding back in March. The investment will allow antibody-drug conjugate (ADC) specialist Pheon to advance its lead ADC program to clinical proof-of-concept and establish of novel ADCs. The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation […]

September 28, 2022 - 3 minutesmins - By Liza Laws

Startup Scout 22 Sep 2022

Cartography Biosciences unearths cancer immunotherapy targets

Despite its meteoric growth in the last twenty years, cancer immunotherapy research is hamstrung by a lack of viable drug targets. Cartography Biosciences is using a single-cell sequencing approach to meet this demand. Immuno-oncology as a field barely existed 20 years ago, but has rapidly grown into a thriving field of biotechnology research. This has […]

September 22, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 6 Sep 2022

Synaffix and Emergence in $360M technology platform deal to develop ADCs

Dutch biotech Synaffix B.V. and German Emergence Therapeutics announced today (September 6) they have entered into a licensing agreement of up to $360 million. The agreement will provide Emergence access on a target-specific basis to Synaffix’s antibody drug conjugate (ADC) technologies made up of Glycoconnect, HydraSpace and SYNtecan E linker payload. Under the terms of […]

September 6, 2022 - 2 minutesmins - By Liza Laws

News and Trends 18 Aug 2022

CSL gets positive results for preventive treatment in patients with hereditary angioedema

Hereditary angioedema (HAE), a condition that causes recurrent attacks of severe swelling, could be prevented by a monoclonal antibody after positive top line phase 3 results were reported. Garadacimab, biotech company CSL’s investigational monoclonal antibody inhibiting factor XIIa, is being developed as a long-term preventive treatment for patients with HAE. Efficacy objectives The study met […]

August 18, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Antibody-drug conjugates

Actinium Pharmaceuticals and Columbia University to study Actimab-A in AML patients

Enhertu’s positive results demonstrate improvement in overall survival

BiVictriX identifies development lead for ADC cancer program

SOTIO exercises option on ADC program

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

Mablink Bioscience receives €31M series A funding for ADC pipeline

Trial starts for treatment of warm autoimmune hemolytic anemia

Araris Biotech closes $24M financing round for ADCs

Pheon Therapeutics launches with $68M in series A funding for treatment of solid tumors

Cartography Biosciences unearths cancer immunotherapy targets

Synaffix and Emergence in $360M technology platform deal to develop ADCs

CSL gets positive results for preventive treatment in patients with hereditary angioedema

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!